Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 2/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.52 |
| ▸ | GSK3B | P49841 | 10/20 | 0.52 |
| ▸ | WNT1 | P04628 | 6/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558686 | 0.90 | GSK3B (0.53) | WNT3ADYRK1AGSK3BWNT1MAPK8 | |
| SCHEMBL559024 | 0.87 | DYRK1A (0.65) | WNT3ADYRK1AGSK3BWNT1MAPK8 | |
| SCHEMBL559364 | 0.85 | MAPK8 (0.70) | WNT3ADYRK1AGSK3BWNT1MAPK8 | |
| SCHEMBL560081 | 0.84 | WNT3A (0.59) | WNT3ADYRK1AGSK3BWNT1MAPK8 | |
| SCHEMBL559251 | 0.82 | DYRK1A (0.51) | DYRK1AGSK3BWNT1USP30ROCK1 | |
| SCHEMBL559705 | 0.81 | DYRK1A (0.47) | WNT3ADYRK1AGSK3BWNT1MAPK8 | |
| SCHEMBL15583582 | 0.80 | ROCK2 (0.55) | WNT3ADYRK1AGSK3BWNT1MAPK8 | |
| SCHEMBL559265 | 0.79 | GSK3B (0.54) | WNT3ADYRK1AGSK3BWNT1MAPK8 | |
| SCHEMBL19515963 | 0.78 | GSK3B (0.65) | DYRK1AGSK3BWNT1USP30ABL1 | |
| SCHEMBL558791 | 0.77 | GSK3B (0.65) | WNT3ADYRK1AGSK3BWNT1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | WNT3A 1899/4885DYRK1A 1064/4885GSK3B 685/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | WNT3A 1899/4885DYRK1A 1064/4885GSK3B 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.